According to Market Screener, on June 26th, a healthcare products and over-the-counter medication company located in Weybridge, England, Haleon, has sold its smoking cessation aid business outside of the United States to Indian pharmaceutical company Dr. Reddy's Laboratories for a maximum of £500 million (approximately $634.2 million) in order to streamline operations and focus on key growth areas.
The company was spun off by GlaxoSmithKline and Pfizer owns a portion of its shares. In a statement on Wednesday (26th), the department said that the funds raised from the sale will be used according to its capital allocation policy and for debt reduction.
Haleon owns popular brands including Sensodyne toothpaste, Aquafresh mouthwash, and over-the-counter medications Panadol and Advil. The company will receive a prepayment of 458 million pounds from the sale, with the remaining amount to be paid in installments next year and in the first half of 2026, contingent upon the achievement of specific performance targets.
The products for sale include nicotine replacement therapies such as patches, lozenges, and gum from brands like Nicotinell, Nicabate, Habitrol, and Thrive.
Haleon stated that the sale is expected to be completed in the early fourth quarter of this year. This will result in a decrease in company revenue of 0.5% and a decrease in operating profit of 1%. The company also added that all other expectations remain unchanged.
The company's CEO, Brian McNamara, stated:
Haleon Company's decision to divest its NRT business from overseas in the United States is another example of the company actively managing its asset portfolio and aligning with our strategy to implement changes to become more agile and competitive.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
